Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 8/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | MELK | Q14680 | 2/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661398 | 0.81 | HRH3 (0.52) | MLNRCYP2D6 | |
| SCHEMBL5663106 | 0.80 | ESR2 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL5660505 | 0.76 | MLNR (0.40) | MLNRSYKAURKBINCENP | |
| SCHEMBL5663067 | 0.70 | SYK (0.48) | MLNRSYKAURKBINCENPHTR2B | |
| SCHEMBL5181956 | 0.70 | MLNR (0.46) | MLNRSYKAURKBINCENPHTR2B | |
| SCHEMBL18584776 | 0.69 | BRD4 (0.69) | — | |
| SCHEMBL5660251 | 0.68 | SYK (0.48) | MLNRSYKAURKBINCENPCYP2D6 | |
| SCHEMBL5168814 | 0.68 | HRH3 (0.47) | MLNRSYKAURKBINCENPCYP2D6 | |
| SCHEMBL5168854 | 0.68 | ESR2 (0.46) | CYP11B1CYP11B2 | |
| SCHEMBL9714132 | 0.66 | GAA (0.40) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | CYP11B1 2159/4885CYP11B2 1823/4885MLNR 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.